Patents by Inventor Garry R. Smith

Garry R. Smith has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tricyclic azaindoles
    Patent number: 8853391
    Abstract: Disclosed are dipyridyl-pyrrole derivative compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to protein kinase signal transduction inhibition, regulation and/or modulation.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: October 7, 2014
    Assignee: Merck Patent GmbH
    Inventors: Bayard R. Huck, Amanda E. Sutton, Benny C. Askew, Jr., Christopher Charles Victor Jones, Garry R. Smith, Nadia Brugger
  • Tricyclic Azaindoles
    Publication number: 20120022060
    Abstract: Disclosed are dipyridyl-pyrrole derivative compounds and analogs thereof, pharmaceutical compositions comprising such compounds and processes for preparing the same. The compounds are useful in the treatment of diseases amenable to protein kinase signal transduction inhibition, regulation and/or modulation.
    Type: Application
    Filed: December 3, 2009
    Publication date: January 26, 2012
    Applicant: MERCK PATENT GMBH
    Inventors: Bayard R. Huck, Amanda E. Sutton, Benny C. Askew, JR., Christopher Charles Victor Jones, Garry R. Smith, Nadia Brugger
  • Integrin receptor antagonists
    Patent number: 6784190
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3, &agr;v&bgr;5, and/or &agr;v&bgr;6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
    Type: Grant
    Filed: July 27, 2001
    Date of Patent: August 31, 2004
    Assignee: Merck & Co., Inc.
    Inventors: Ben C. Askew, Paul J. Coleman, Mark E. Duggan, Wasyl Halczenko, George D. Hartman, Cecilia A. Hunt, John H. Hutchinson, Robert S. Meissner, Michael A. Patane, Garry R. Smith, Jiabing Wang
  • Integrin receptor antagonists
    Patent number: 6413955
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as vitronectin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.
    Type: Grant
    Filed: October 2, 2000
    Date of Patent: July 2, 2002
    Assignee: Merck & Co., Inc.
    Inventors: Ben C. Askew, Garry R. Smith
  • Integrin receptor antagonists
    Publication number: 20020010176
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3, &agr;v&bgr;5, and/or &agr;v&bgr;6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
    Type: Application
    Filed: July 28, 2001
    Publication date: January 24, 2002
    Inventors: Ben C. Askew, Paul J. Coleman, Mark E. Duggan, Wasyl Halczenko, George D. Hartman, Cecilia A. Hunt, John H. Hutchinson, Robert S. Meissner, Michael A. Patane, Garry R. Smith, Jiabing Wang
  • Integrin receptor antagonists
    Patent number: 6048861
    Abstract: The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors .alpha.v.beta.3, .alpha.v.beta.5, and/or .alpha.v.beta.6 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, wound healing, viral disease, tumor growth, and metastasis.
    Type: Grant
    Filed: December 15, 1998
    Date of Patent: April 11, 2000
    Assignee: Merck & Co., Inc.
    Inventors: Ben C. Askew, Paul J. Coleman, Mark E. Duggan, Wasyl Halczenko, George D. Hartman, Cecilia A. Hunt, John H. Hutchinson, Robert S. Meissner, Michael A. Patane, Garry R. Smith, Jiabing Wang
  • N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1H-benzo?B!?1,4!diazepi n-3yl)-acetamides
    Patent number: 5726171
    Abstract: This invention is concerned with novel compounds represented by structural formula I ##STR1## which are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: March 13, 1996
    Date of Patent: March 10, 1998
    Inventors: David A. Claremon, Nigel Liverton, Garry R. Smith, Harold G. Selnick
  • N-(2,4-Dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3yl) -3- amides
    Patent number: 5691331
    Abstract: This invention is concerned with novel compounds represented by structural formula I ##STR1## which are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: November 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, Roger M. Freidinger, Nigel Liverton, Harold G. Selnick, Garry R. Smith
  • N-(2,4-dioxo-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-3-yl)-3-amides
    Patent number: 5691332
    Abstract: This invention is concerned with novel compounds represented by structural formula I ##STR1## which are useful in the treatment of arrhythmia.
    Type: Grant
    Filed: August 19, 1996
    Date of Patent: November 25, 1997
    Assignee: Merck & Co., Inc.
    Inventors: David A. Claremon, Roger M. Freidinger, Nigel Liverton, Harold G. Selnick, Garry R. Smith
  • Dynamic roll control system for a motor vehicle
    Patent number: 5480186
    Abstract: A dynamic roll control system for a suspension system of a motor vehicle (10) provides dynamic roll stabilization during motor vehicle steering maneuvers by predicting a theoretical lateral weight transfer and corresponding degree of motor vehicle roll. A roll control signal (116) is generated for controlling a roll control valve (110) in response thereto. An actuation flow (98) is distributed to roll control actuators (72) by a distribution valve (132) to resist the predicted roll.
    Type: Grant
    Filed: December 23, 1994
    Date of Patent: January 2, 1996
    Assignee: Ford Motor Company
    Inventor: Garry R. Smith
  • Vehicle door pivoted side glass
    Patent number: 5009461
    Abstract: A vehicle door assembly which is hingedly connected to a side pillar of an automotive vehicle and which includes an operating mechanism for automatically pivoting a side window of the door assembly from an inner severely inwardly sloped position toward an outer generally vertical position in response to movement of the door assembly from a closed position toward an open position so as to permit easy entrance into exit from the vehicle.
    Type: Grant
    Filed: May 31, 1988
    Date of Patent: April 23, 1991
    Assignee: General Motors Corporation
    Inventors: Garry R. Smith-Horn, Robert J. Wendt